Clinical-stage niche Inhibitex is a clinical-stage biopharma focused on infectious disease therapies, presenting opportunities to engage with early-stage programs, potential collaboration on clinical development, and partnerships around novel treatments for herpes zoster, HCV, and S. aureus.

Small to mid biotech With 11-50 employees and revenue in the low millions, there is appetite for partnerships that leverage outsourcing, CRO/CMO collaborations, and licensing deals to accelerate development while managing internal capacity.

Diverse infectious portfolio A diversified pipeline addressing viral and bacterial infections creates multiple entry points for MSDs, co-development discussions, and cross-therapy strategic alliances to expand market reach and share of voice in infectious disease therapy.

North American focus Based in Alpharetta, GA, there are regional sales opportunities with U.S. hospitals, academic medical centers, and federal or state-funded research programs seeking innovative infectious disease solutions.

Growth signals Revenue presence indicates market validation; potential buyers or partners may seek licensing, collaboration on later-stage trials, or acquisition options as the company scales its pipeline and resources.